BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38742107)

  • 1. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
    Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
    Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
    Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani HH; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
    J Virol; 2023 Sep; 97(9):e0062823. PubMed ID: 37676002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
    Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
    Niu S; Zhao Z; Liu Z; Rong X; Chai Y; Bai B; Han P; Shang G; Ren J; Wang Y; Zhao X; Liu K; Tian W-x; Wang Q; Gao GF
    J Virol; 2024 Mar; 98(3):e0115723. PubMed ID: 38305152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice.
    He Y; Henley J; Sell P; Comai L
    Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice.
    Liu S; Selvaraj P; Sangare K; Luan B; Wang TT
    Cell Rep; 2022 Sep; 40(11):111359. PubMed ID: 36075211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
    Radvak P; Kwon HJ; Kosikova M; Ortega-Rodriguez U; Xiang R; Phue JN; Shen RF; Rozzelle J; Kapoor N; Rabara T; Fairman J; Xie H
    Nat Commun; 2021 Nov; 12(1):6559. PubMed ID: 34772941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 spike D614G change enhances replication and transmission.
    Zhou B; Thao TTN; Hoffmann D; Taddeo A; Ebert N; Labroussaa F; Pohlmann A; King J; Steiner S; Kelly JN; Portmann J; Halwe NJ; Ulrich L; Trüeb BS; Fan X; Hoffmann B; Wang L; Thomann L; Lin X; Stalder H; Pozzi B; de Brot S; Jiang N; Cui D; Hossain J; Wilson MM; Keller MW; Stark TJ; Barnes JR; Dijkman R; Jores J; Benarafa C; Wentworth DE; Thiel V; Beer M
    Nature; 2021 Apr; 592(7852):122-127. PubMed ID: 33636719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptation of SARS-CoV-2 to ACE2
    Li K; Verma A; Li P; Ortiz ME; Hawkins GM; Schnicker NJ; Szachowicz PJ; Pezzulo AA; Wohlford-Lenane CL; Kicmal T; Meyerholz DK; Gallagher T; Perlman S; McCray PB
    J Virol; 2024 Jan; 98(1):e0151023. PubMed ID: 38168680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.